

Martin Metz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4344912/publications.pdf>

Version: 2024-02-01

246
papers

16,145
citations

13865

67
h-index

20358

116
g-index

280
all docs

280
docs citations

280
times ranked

9470
citing authors

#	ARTICLE	IF	CITATIONS
1	The EAACI/GA ² LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1393-1414.	5.7	1,008
2	The EAACI/GA ² LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 868-887.	5.7	912
3	The international EAACI/GA ² LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 734-766.	5.7	392
4	Mast Cells Can Enhance Resistance to Snake and Honeybee Venoms. <i>Science</i> , 2006, 313, 526-530.	12.6	333
5	Control of murine hair follicle regression (catagen) by TGF β 1 <i>in vivo</i> . <i>FASEB Journal</i> , 2000, 14, 752-760.	0.5	301
6	Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. <i>Nature</i> , 2004, 432, 512-516.	27.8	275
7	Mast cells in the promotion and limitation of chronic inflammation. <i>Immunological Reviews</i> , 2007, 217, 304-328.	6.0	275
8	Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1365-1372.e6.	2.9	268
9	The definition, diagnostic testing, and management of chronic inducible urticarias - The EAACI/GA ² LEN/EDF/UNEV consensus recommendations 2016 update and revision. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 780-802.	5.7	268
10	Mast cells â€“ key effector cells in immune responses. <i>Trends in Immunology</i> , 2007, 28, 234-241.	6.8	264
11	Autoimmune chronic spontaneous urticaria: What we know and what we do not know. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1772-1781.e1.	2.9	240
12	Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: A retrospective clinical analysis. <i>Journal of Dermatological Science</i> , 2014, 73, 57-62.	1.9	222
13	IgE Mediated Autoallergy against Thyroid Peroxidase â€“ A Novel Pathomechanism of Chronic Spontaneous Urticaria?. <i>PLoS ONE</i> , 2011, 6, e14794.	2.5	216
14	The potential pharmacologic mechanisms of omalizumab in patients with chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2015, 135, 337-342.e2.	2.9	208
15	Quality of life in patients with chronic urticaria is differentially impaired and determined by psychiatric comorbidity. <i>British Journal of Dermatology</i> , 2006, 154, 294-298.	1.5	189
16	What is the physiological function of mast cells?. <i>Experimental Dermatology</i> , 2003, 12, 886-886.	2.9	187
17	Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 638-649.	2.9	187
18	Ligelizumab for Chronic Spontaneous Urticaria. <i>New England Journal of Medicine</i> , 2019, 381, 1321-1332.	27.0	187

#	ARTICLE	IF	CITATIONS
19	Development and construct validation of the angioedema quality of life questionnaire. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1289-1298.	5.7	182
20	Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1059-1061.e1.	2.9	167
21	The role and relevance of mast cells in urticaria. <i>Immunological Reviews</i> , 2018, 282, 232-247.	6.0	165
22	IL-9 Production by Regulatory T Cells Recruits Mast Cells That Are Essential for Regulatory T Cell-Induced Immune Suppression. <i>Journal of Immunology</i> , 2011, 186, 83-91.	0.8	160
23	TLR3-induced activation of mast cells modulates CD8+ T-cell recruitment. <i>Blood</i> , 2005, 106, 978-987.	1.4	157
24	A Beneficial Role for Immunoglobulin E in Host Defense against Honeybee Venom. <i>Immunity</i> , 2013, 39, 963-975.	14.3	151
25	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1059-1065.	2.4	150
26	Successful treatment of solar urticaria with anti-immunoglobulin E therapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 1563-1565.	5.7	149
27	Development, validation, and initial results of the Angioedema Activity Score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1185-1192.	5.7	147
28	Mast cells orchestrate type 2 immunity to helminths through regulation of tissue-derived cytokines. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, 6644-6649.	7.1	145
29	The definition and diagnostic testing of physical and cholinergic urticarias â€“ EAACI/GA ² /LEN/EDF/UNEV consensus panel recommendations. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2009, 64, 1715-1721.	5.7	143
30	Mast cell chymase reduces the toxicity of Gila monster venom, scorpion venom, and vasoactive intestinal polypeptide in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 4180-4191.	8.2	134
31	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. <i>International Archives of Allergy and Immunology</i> , 2011, 154, 177-180.	2.1	133
32	Early macrophage influx to sites of cutaneous granuloma formation is dependent on MIP-1 α released from neutrophils recruited by mast cell-derived TNF α . <i>Blood</i> , 2003, 101, 210-215.	1.4	130
33	Comorbidity of chronic spontaneous urticaria and autoimmune thyroid diseases: A systematic review. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 1440-1460.	5.7	124
34	Skin mast cells control T cell-dependent host defense in <i>Leishmania major</i> infections. <i>FASEB Journal</i> , 2006, 20, 2460-2467.	0.5	123
35	Retreatment With Omalizumab Results in Rapid Remission in Chronic Spontaneous and Inducible Urticaria. <i>JAMA Dermatology</i> , 2014, 150, 288.	4.1	123
36	Autologous Whole Blood Injections to Patients with Chronic Urticaria and a Positive Autologous Serum Skin Test: A Placebo-Controlled Trial. <i>Dermatology</i> , 2006, 212, 150-159.	2.1	120

#	ARTICLE	IF	CITATIONS
37	Immunoglobulin E-Mediated Autoimmunity. <i>Frontiers in Immunology</i> , 2018, 9, 689.	4.8	116
38	Neurotensin increases mortality and mast cells reduce neurotensin levels in a mouse model of sepsis. <i>Nature Medicine</i> , 2008, 14, 392-398.	30.7	114
39	Clinical efficacy of omalizumab in chronic spontaneous urticaria is associated with a reduction of FċRI-positive cells in the skin. <i>Theranostics</i> , 2017, 7, 1266-1276.	10.0	113
40	Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2008, 63, 247-249.	5.7	112
41	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. <i>Acta Dermato-Venereologica</i> , 2011, 91, 557-561.	1.3	110
42	Definition, aims, and implementation of ² GA² Urticaria Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1210-1218.	5.7	110
43	Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 113-117.	5.7	108
44	Effect of omalizumab on angioedema in H ₁ -antihistamine-resistant chronic spontaneous urticaria patients: results from XACT, a randomized controlled trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1135-1144.	5.7	108
45	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 321-333.	2.1	108
46	Mast cell functions in the innate skin immune system. <i>Immunobiology</i> , 2008, 213, 251-260.	1.9	104
47	IL-15 constrains mast cell-dependent antibacterial defenses by suppressing chymase activities. <i>Nature Medicine</i> , 2007, 13, 927-934.	30.7	102
48	Effector and potential immunoregulatory roles of mast cells in IgE-associated acquired immune responses. <i>Current Opinion in Immunology</i> , 2006, 18, 751-760.	5.5	100
49	A new role for neurotrophins: involvement of brain-derived neurotrophic factor and neurotrophin-4 in hair cycle control. <i>FASEB Journal</i> , 1999, 13, 395-410.	0.5	93
50	Eosinopenia, in Chronic Spontaneous Urticaria, Is Associated with High Disease Activity, Autoimmunity, and Poor Response to Treatment. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 318-325.e5.	3.8	93
51	Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 864-867.e5.	2.9	92
52	Skin Barrier Damage and Itch: Review of Mechanisms, Topical Management and Future Directions. <i>Acta Dermato-Venereologica</i> , 2019, 99, 1201-1209.	1.3	92
53	Murine mast cells secrete a unique profile of cytokines and prostaglandins in response to distinct TLR2 ligands. <i>Experimental Dermatology</i> , 2009, 18, 437-444.	2.9	91
54	Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1311-1320.	2.9	89

#	ARTICLE	IF	CITATIONS
55	Mast cells as protectors of health. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, S4-S18.	2.9	88
56	Serlopitant reduced pruritus in patients with prurigo nodularis in a phase 2, randomized, placebo-controlled trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1395-1402.	1.2	82
57	A New Role for Neurotrophin-3. <i>American Journal of Pathology</i> , 1998, 153, 785-799.	3.8	81
58	Control of <i>Pseudomonas aeruginosa</i> Skin Infections in Mice Is Mast Cell-Dependent. <i>American Journal of Pathology</i> , 2007, 170, 1910-1916.	3.8	80
59	The Urticaria Activity Scoreâ€™ Validity, Reliability, and Responsiveness. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1185-1190.e1.	3.8	78
60	Potential blood biomarkers in chronic spontaneous urticaria. <i>Clinical and Experimental Allergy</i> , 2017, 47, 19-36.	2.9	76
61	Mast cellâ€™driven skin inflammation is impaired in the absence of sensory nerves. <i>Journal of Allergy and Clinical Immunology</i> , 2008, 121, 955-961.	2.9	75
62	Methods report on the development of the 2013 revision and update of the <scp>EAACI</scp>/<scp>GA²</sup>LEN</scp>/<scp>EDF</scp>/<scp>WAO</scp> guideline for the definition, classification, diagnosis, and management of urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, e1-29.	5.7	75
63	Mast cells rescue implantation defects caused by c-kit deficiency. <i>Cell Death and Disease</i> , 2013, 4, e462-e462.	6.3	74
64	Executive summary of the methods report for â€™The EAACI/GA²</sup>LEN/EDF/WAO Guideline for the Definition, Classification, Diagnosis and Management of Urticaria. The 2017 Revision and Updateâ€™™. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1145-1146.	5.7	74
65	Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2406-2408.	5.7	74
66	The role of interleukin-1 in allergy-related disorders. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 477-484.	2.3	73
67	Omalizumab is effective in symptomatic dermatographismâ€™ results of a randomized placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 870-873.e5.	2.9	73
68	Autoimmune chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1819-1831.	2.9	73
69	Understanding human mast cells: lesson from therapies for allergic and non-allergic diseases. <i>Nature Reviews Immunology</i> , 2022, 22, 294-308.	22.7	72
70	A randomized, doubleâ€™blind, comparative study of standardâ€™dose rabeprazole and highâ€™dose omeprazole in gastroâ€™esophageal reflux disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2002, 16, 479-485.	3.7	71
71	New biological treatments for asthma and skin allergies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 546-560.	5.7	70
72	Mas-related G proteinâ€™coupled receptor X2 and its activators in dermatologic allergies. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 456-469.	2.9	70

#	ARTICLE	IF	CITATIONS
73	Responsiveness and minimal important difference of the urticaria control test. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1710-1713.e11.	2.9	68
74	Frequency and clinical implications of skin autoreactivity to serum versus plasma in patients with chronic urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2009, 123, 705-706.	2.9	67
75	Pathophysiology of itch and new treatments. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2011, 11, 420-427.	2.3	66
76	Peltier effect-based temperature challenge: An improved method for diagnosing cold urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2004, 114, 1224-1225.	2.9	63
77	Chronic pruritus - pathogenesis, clinical aspects and treatment. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2010, 24, 1249-1260.	2.4	62
78	Rupatadine and its effects on symptom control, stimulation time, and temperature thresholds in patients with acquired cold urticaria. <i>Annals of Allergy, Asthma and Immunology</i> , 2010, 104, 86-92.	1.0	62
79	Substance P Is Upregulated in the Serum of Patients with Chronic Spontaneous Urticaria. <i>Journal of Investigative Dermatology</i> , 2014, 134, 2833-2836.	0.7	61
80	A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1730-1732.	2.9	60
81	Omalizumab Updosing in Chronic Spontaneous Urticaria: an Overview of Real-World Evidence. <i>Clinical Reviews in Allergy and Immunology</i> , 2020, 59, 38-45.	6.5	60
82	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. <i>Journal of Allergy and Clinical Immunology</i> , 2010, 126, 665-666.	2.9	59
83	The role of eosinophils in chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 1510-1516.	2.9	59
84	Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 1793-1802.e2.	3.8	58
85	Innate immunity and allergy in the skin. <i>Current Opinion in Immunology</i> , 2009, 21, 687-693.	5.5	57
86	Looking forward to new targeted treatments for chronic spontaneous urticaria. <i>Clinical and Translational Allergy</i> , 2017, 7, 1.	3.2	57
87	S2-Leitlinie zur Diagnostik und Therapie des chronischen Pruritus - Update - Kurzversion. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 860-873.	0.8	56
88	Mast cells are critical for controlling the bacterial burden and the healing of infected wounds. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 20500-20504.	7.1	55
89	Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?. <i>Experimental Dermatology</i> , 2006, 15, 913-916.	2.9	54
90	Role and Relevance of Mast Cells in Fungal Infections. <i>Frontiers in Immunology</i> , 2012, 3, 146.	4.8	54

#	ARTICLE	IF	CITATIONS
91	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 816-819.	5.7	53
92	German Version of ItchyQoL: Validation and Initial Clinical Findings. <i>Acta Dermato-Venereologica</i> , 2013, 93, 562-568.	1.3	53
93	Mast cells: makers and breakers of allergic inflammation. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2009, 9, 427-430.	2.3	52
94	Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 751-754.e5.	2.9	52
95	Benefit from reslizumab treatment in a patient with chronic spontaneous urticaria and cold urticaria. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, e112-e113.	2.4	52
96	Fenebrutinib in H1 antihistamine-refractory chronic spontaneous urticaria: a randomized phase 2 trial. <i>Nature Medicine</i> , 2021, 27, 1961-1969.	30.7	52
97	The <i>status quo</i> and <i>quo vadis</i> of mast cells. <i>Experimental Dermatology</i> , 2005, 14, 923-929.	2.9	51
98	Inflammatory Murine Skin Responses to UV-B Light Are Partially Dependent on Endothelin-1 and Mast Cells. <i>American Journal of Pathology</i> , 2006, 169, 815-822.	3.8	51
99	Benefit of mepolizumab treatment in a patient with chronic spontaneous urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 477-478.	0.8	51
100	Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: XACT study data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 576-584.	5.7	51
101	Unmet Medical Needs in Chronic, Non-communicable Inflammatory Skin Diseases. <i>Frontiers in Medicine</i> , 0, 9, .	2.6	51
102	Mast cells protect from post-traumatic spinal cord damage in mice by degrading inflammation-associated cytokines via mouse mast cell protease 4. <i>Neurobiology of Disease</i> , 2014, 62, 260-272.	4.4	50
103	Mast Cells Limit the Exacerbation of Chronic Allergic Contact Dermatitis in Response to Repeated Allergen Exposure. <i>Journal of Immunology</i> , 2016, 197, 4240-4246.	0.8	50
104	Comparison and interpretability of the available urticaria activity scores. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 251-255.	5.7	50
105	Validation of the Angioedema Control Test (AECT) – A Patient-Reported Outcome Instrument for Assessing Angioedema Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2050-2057.e4.	3.8	50
106	<i>Fasciola hepatica</i> Tegumental Coat Impairs Mast Cells' Ability To Drive Th1 Immune Responses. <i>Journal of Immunology</i> , 2013, 190, 2873-2879.	0.8	49
107	Omalizumab in chronic urticaria. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 406-411.	2.3	48
108	Mast cells protect from post-traumatic brain inflammation by the mast cell-specific chymase mouse mast cell protease-4. <i>FASEB Journal</i> , 2013, 27, 920-929.	0.5	48

#	ARTICLE	IF	CITATIONS
109	Non-pathogenic commensal <i>Escherichia coli</i> bacteria can inhibit degranulation of mast cells. <i>Experimental Dermatology</i> , 2008, 17, 427-435.	2.9	47
110	Development of the Angioedema Control Test – A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1165-1177.	5.7	47
111	IFSI-guideline on chronic prurigo including prurigo nodularis. <i>Itch (Philadelphia, Pa)</i> , 2020, 5, e42-e42.	0.2	47
112	Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2010, 65, 1494-1495.	5.7	46
113	Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 949-952.	5.7	46
114	Autoimmune Diseases Are Linked to Type IIb Autoimmune Chronic Spontaneous Urticaria. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 545.	2.9	46
115	Chronic nodular prurigo: clinical profile and burden. A European cross-sectional study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2373-2383.	2.4	44
116	Atopic dermatitis in children: management of pruritus. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2012, 26, 2-8.	2.4	43
117	Pruritus: an overview of current concepts. <i>Veterinary Dermatology</i> , 2011, 22, 121-131.	1.2	41
118	Role of Substance P and Its Receptor Neurokinin 1 in Chronic Prurigo: A Randomized, Proof-of-Concept, Controlled Trial with Topical Aprepitant. <i>Acta Dermato-Venereologica</i> , 2018, 98, 26-31.	1.3	40
119	Critical role of IL-10 in the induction of low zone tolerance to contact allergens. <i>Journal of Clinical Investigation</i> , 2003, 112, 432-439.	8.2	40
120	Aprepitant in Anti-histamine-refractory Chronic Nodular Prurigo: A Multicentre, Randomized, Double-blind, Placebo-controlled, Cross-over, Phase-II trial (APREPRU). <i>Acta Dermato-Venereologica</i> , 2019, 99, 379-385.	1.3	40
121	Revisions to the international guidelines on the diagnosis and therapy of chronic urticaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 971-978.	0.8	39
122	Acquired cold urticaria symptoms can be safely prevented by ebastine. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2007, 62, 1465-1468.	5.7	38
123	A novel method to generate and culture human mast cells: Peripheral CD34+ stem cell-derived mast cells (PSCMCs). <i>Journal of Immunological Methods</i> , 2014, 413, 62-68.	1.4	37
124	Anaphylaxis caused by mosquito allergy in systemic mastocytosis. <i>Lancet, The</i> , 2013, 382, 1380.	18.7	35
125	Imaging glioma biology: spatial comparison of amino acid PET, amide proton transfer, and perfusion-weighted MRI in newly diagnosed gliomas. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1468-1475.	6.4	35
126	Distinct Roles for Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Controlling the Rate of Hair Follicle Morphogenesis. <i>Journal of Investigative Dermatology</i> , 2000, 114, 314-320.	0.7	32

#	ARTICLE	IF	CITATIONS
127	Omalizumab normalizes the gene expression signature of lesional skin in patients with chronic spontaneous urticaria: A randomized, double-blind, placebo-controlled study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 141-151.	5.7	32
128	Pruritus and sleep disturbances in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2020, 312, 103-111.	1.9	32
129	T cell killing by tolerogenic dendritic cells protects mice from allergy. <i>Journal of Clinical Investigation</i> , 2011, 121, 3860-3871.	8.2	31
130	Neurotrophin-3 regulates mast cell functions in neonatal mouse skin. <i>Experimental Dermatology</i> , 2004, 13, 273-281.	2.9	29
131	Histamine, TNF, C5a, IL-6, -9, -18, -31, -33, TSLP, Neopterin, and VEGF are not elevated in chronic spontaneous urticaria. <i>Journal of Dermatological Science</i> , 2013, 70, 222-225.	1.9	29
132	Definition, aims, and implementation of GA ² /LEN/HAEi Angioedema Centers of Reference and Excellence. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 2115-2123.	5.7	29
133	A group of cationic amphiphilic drugs activates MRGPRX2 and induces scratching behavior in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 148, 506-522.e8.	2.9	29
134	Development and Validation of a Questionnaire for the Assessment of Pelvic Floor Disorders and Their Risk Factors During Pregnancy and Post Partum. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 358-365.	1.8	29
135	Polidocanol inhibits cowhage -but not histamine-induced itch in humans. <i>Experimental Dermatology</i> , 2014, 23, 922-923.	2.9	28
136	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 691-700.	1.2	28
137	Mast cells protect from skin tumor development and limit tumor growth during cutaneous <i>de novo</i> carcinogenesis in a <i>K</i> -dependent mouse model. <i>Experimental Dermatology</i> , 2014, 23, 159-164.	2.9	27
138	A Role for Bax in the Regulation of Apoptosis in Mouse Mast Cells. <i>Journal of Investigative Dermatology</i> , 2000, 114, 1205-1206.	0.7	26
139	Chronic pruritus associated with dermatologic disease in infancy and childhood: Update from an interdisciplinary group of dermatologists and pediatricians. <i>Pediatric Allergy and Immunology</i> , 2013, 24, 527-539.	2.6	26
140	Neues von der internationalen Leitlinie f¼r Diagnostik und Therapie der chronischen Urtikaria. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 971-979.	0.8	26
141	Diagnosis and treatment of chronic inducible urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2550-2553.	5.7	26
142	Management of urticarial vasculitis: A worldwide physician perspective. <i>World Allergy Organization Journal</i> , 2020, 13, 100107.	3.5	26
143	Sustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2175-2184.	5.7	26
144	Mast cells, cortistatin, and its receptor, MRGPRX2, are linked to the pathogenesis of chronic prurigo. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1998-2009.e5.	2.9	26

#	ARTICLE	IF	CITATIONS
145	Patients with chronic urticaria exhibit increased rates of sensitisation to <i>Candida albicans</i> , but not to common moulds. <i>Mycoses</i> , 2009, 52, 334-338.	4.0	25
146	Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review. <i>Acta Dermato-Venereologica</i> , 2019, 99, 905-906.	1.3	25
147	Real-life treatment of cholinergic urticaria with omalizumab. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 788-791.e8.	2.9	25
148	Position Statement: Linear prurigo is a subtype of chronic prurigo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 263-266.	2.4	24
149	Rupatadine for the treatment of allergic rhinitis and urticaria. <i>Expert Review of Clinical Immunology</i> , 2011, 7, 15-20.	3.0	23
150	S2k Guidelines for the diagnosis and treatment of chronic pruritus – update – short version. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 860-872.	0.8	23
151	Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes?. <i>Experimental Dermatology</i> , 2006, 15, 913-929.	2.9	23
152	Mast cells determine the magnitude of bacterial toxin-induced skin inflammation. <i>Experimental Dermatology</i> , 2009, 18, 160-166.	2.9	22
153	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. <i>Archives of Dermatology</i> , 2011, 147, 1221.	1.4	22
154	Human Mast Cell Tryptase Is a Potential Treatment for Snakebite Envenoming Across Multiple Snake Species. <i>Frontiers in Immunology</i> , 2018, 9, 1532.	4.8	22
155	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2073-2075.	5.7	22
156	Mast cells and IgE in defense against lethality of venoms: Possible benefit of allergy. <i>Allergo Journal International</i> , 2020, 29, 46-62.	2.0	22
157	Brain-derived neurotrophic factor, neurotrophin-3, and neurotrophin-4 act as "epitheliotrophins" in murine skin. <i>Laboratory Investigation</i> , 1999, 79, 557-72.	3.7	22
158	Prevention of signs and symptoms of dermographic urticaria by single-dose ebastine 20 mg. <i>Clinical and Experimental Dermatology</i> , 2009, 34, e137-e140.	1.3	21
159	The Diagnostic Workup in Chronic Spontaneous Urticaria – What to Test and Why. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2274-2283.	3.8	21
160	Chronic Nodular Prurigo: A European Cross-sectional Study of Patient Perspectives on Therapeutic Goals and Satisfaction. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00403.	1.3	20
161	Treatment of notalgia paraesthetica with an 8% capsaicin patch. <i>British Journal of Dermatology</i> , 2011, 165, 1359-1361.	1.5	18
162	Membrane-bound stem cell factor is the major but not only driver of fibroblast-induced murine skin mast cell differentiation. <i>Experimental Dermatology</i> , 2017, 26, 255-262.	2.9	18

#	ARTICLE	IF	CITATIONS
163	Effects of Antihistamines on Innate Immune Responses to Severe Bacterial Infection in Mice. <i>International Archives of Allergy and Immunology</i> , 2011, 155, 355-360.	2.1	17
164	Effective Control of Recalcitrant Pruritus by Bevacizumab: A Possible Role for Vascular Endothelial Growth Factor in Chronic Itch?. <i>Acta Dermato-Venereologica</i> , 2013, 93, 175-179.	1.3	17
165	Skin provocation tests may help to diagnose atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1745-1752.	5.7	17
166	In chronic spontaneous urticaria, high numbers of dermal endothelial cells, but not mast cells, are linked to recurrent angio-oedema. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 131-136.	1.3	17
167	Protocols for the Induction and Evaluation of Systemic Anaphylaxis in Mice. <i>Methods in Molecular Biology</i> , 2013, 1032, 133-138.	0.9	17
168	Mast cells cultured from IL-3-treated mice show impaired responses to bacterial antigen stimulation. <i>Inflammation Research</i> , 2012, 61, 79-85.	4.0	16
169	The effects of <i>Fasciola hepatica</i> tegumental antigens on mast cell function. <i>International Journal for Parasitology</i> , 2013, 43, 531-539.	3.1	16
170	Omalizumab may not inhibit mast cell and basophil activation <i>in vitro</i> . <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 1832-1836.	2.4	16
171	Lower IgA Levels in Chronic Spontaneous Urticaria Are Associated With Lower IgE Levels and Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 657211.	4.8	15
172	Effects of a topical treatment with spleen tyrosine kinase inhibitor in healthy subjects and patients with cold urticaria or chronic spontaneous urticaria: Results of a phase 1a/b randomised double-blind placebo-controlled study. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4797-4808.	2.4	15
173	Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 688-697.	2.4	15
174	Best practices, new perspectives and the perfect emollient: optimizing the management of contact dermatitis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 241-251.	2.2	14
175	Retardation of Hair Follicle Development by the Deletion of TrkC, High-Affinity Neurotrophin-3 Receptor. <i>Journal of Investigative Dermatology</i> , 1999, 113, 425-427.	0.7	13
176	Palliative treatment of skin metastases in dermatology. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1041-1046.	0.8	13
177	Expert consensus on practical aspects in the treatment of chronic urticaria. <i>Allergo Journal International</i> , 2021, 30, 64-75.	2.0	13
178	Magistralrezeptur und Pruritustherapie - Was ist etabliert, was hat sich bewährt, was ist neu?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1049-1056.	0.8	12
179	Mast cells: Promoters of health and modulators of disease. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 144, S1-S3.	2.9	12
180	Characterization of the effects on pruritus by novel treatments for atopic dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2022, 20, 150-156.	0.8	12

#	ARTICLE	IF	CITATIONS
181	Evidence that the endothelin A receptor can enhance IgE-dependent anaphylaxis in mice. <i>Journal of Allergy and Clinical Immunology</i> , 2011, 128, 424-426.e1.	2.9	11
182	The EAACI/GA2LEN/EDF/WAO Guideline for the definition, classification, diagnosis, and management of urticaria: the 2013 revision and update. <i>Przegląd Dermatologiczny</i> , 2015, 2, 155-179.	0.1	11
183	Increased angiogenesis and VEGF expression correlates with disease severity in prurigo patients. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2016, 30, 1357-1361.	2.4	11
184	Poster Discussion Session PDS. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 118-272.	5.7	11
185	Itch Management: Topical Agents. <i>Current Problems in Dermatology</i> , 2016, 50, 40-45.	0.7	11
186	Mast cells are critical for the limitation of thrombin-induced skin inflammation. <i>Experimental Dermatology</i> , 2018, 27, 50-57.	2.9	11
187	Miltefosine: a novel treatment option for mast cell-mediated diseases. <i>Journal of Dermatological Treatment</i> , 2013, 24, 244-249.	2.2	10
188	Galactose-1,3-Galactose Allergy Is Not a Hitherto Unrecognized Cause of Chronic Spontaneous Urticaria. <i>International Archives of Allergy and Immunology</i> , 2015, 167, 250-252.	2.1	10
189	Use of biologics in chronic spontaneous urticaria – beyond omalizumab therapy?. <i>Allergologie Select</i> , 2021, 5, 89-95.	3.1	10
190	Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial. <i>Dermatology and Therapy</i> , 2015, 5, 217-230.	3.0	9
191	Chymase-Cre; Mcl-1fl/fl Mice Exhibit Reduced Numbers of Mucosal Mast Cells. <i>Frontiers in Immunology</i> , 2019, 10, 2399.	4.8	9
192	The response to treatment in chronic spontaneous urticaria depends on how it is measured. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2055-2056.e4.	3.8	9
193	Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 910-922.	1.2	9
194	The Classification, Pathogenesis, Diagnostic Workup, and Management of Urticaria: An Update. <i>Handbook of Experimental Pharmacology</i> , 2021, 268, 117-133.	1.8	9
195	Treatments for chronic pruritus outside of the box. <i>Experimental Dermatology</i> , 2019, 28, 1476-1481.	2.9	8
196	Severe contact dermatitis caused by urushiol in Japanese lacquer. <i>Contact Dermatitis</i> , 2019, 80, 55-56.	1.4	8
197	In Chronic Spontaneous Urticaria, Comorbid Depression Linked to Higher Disease Activity, and Substance P Levels. <i>Frontiers in Psychiatry</i> , 2021, 12, 667978.	2.6	8
198	Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3810-3813.	5.7	8

#	ARTICLE	IF	CITATIONS
199	A comprehensive, tri-national, cross-sectional analysis of characteristics and impact of pruritus in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2064-2075.	2.4	8
200	Erfolgreiche Behandlung des hereditären Angioödems mit dem Bradykinin-B2-Rezeptor-Antagonisten Icatibant. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 272-274.	0.8	7
201	Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1755-1761.	2.4	7
202	Evidence for Non-Allergic Mast Cell Activation in Pollen-Associated Inflammation. <i>Journal of Investigative Dermatology</i> , 2011, 131, 987-990.	0.7	6
203	Magistral formulations and pruritus therapy – What is established, what is confirmed, what is new?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2013, 11, 1049-1055.	0.8	6
204	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1166-1167.	2.9	6
205	Effective treatment with mepolizumab in a patient with refractory Wells syndrome. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 737-739.	0.8	6
206	A distinctive bullous skin reaction associated with enfortumab vedotin treatment for metastatic urothelial cancer: A case report. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 1781-1783.	0.8	6
207	Successful treatment of hereditary angioedema with bradykinin B2-receptor antagonist icatibant. <i>JDDG - Journal of the German Society of Dermatology</i> , 2010, 8, 272-274.	0.8	5
208	Anti-pruritic Effect of Sertaconazole 2% Cream in Atopic Dermatitis Subjects: A Prospective, Randomized, Double-blind, Vehicle-controlled, Multi-centre Clinical Trial of Efficacy, Safety and Local Tolerability. <i>Acta Dermato-Venereologica</i> , 2014, 96, 792-6.	1.3	5
209	H1-antihistamine inhibition of histamine- and codeine-induced wheals does not predict response in chronic cold urticaria. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2043-2044.	3.8	5
210	Characterization of cowhage-induced pruritus in inflamed and non-inflamed skin. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 202-206.	2.4	5
211	Effectiveness of canakinumab treatment in Schnitzler's syndrome: a multi-center randomized placebo-controlled study. <i>Pediatric Rheumatology</i> , 2015, 13, .	2.1	4
212	Effective treatment of a lymphocytic variant of hypereosinophilic syndrome with reslizumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1171-1172.	0.8	4
213	Prevalence and relevance of skin autoreactivity in chronic urticaria. <i>Expert Review of Dermatology</i> , 2009, 4, 655-663.	0.3	3
214	Flare Size but Not Intensity Reflects Histamine-Induced Itch. <i>Skin Pharmacology and Physiology</i> , 2020, 33, 244-252.	2.5	3
215	Baricitinib rapidly and sustainably relieves a patient from chronic pruritus of unknown origin refractory to dupilumab. <i>JAAD Case Reports</i> , 2021, 15, 36-38.	0.8	3
216	Mast Cell-Mediated Reactions In Vivo. <i>Methods in Molecular Biology</i> , 2014, 1192, 239-247.	0.9	3

#	ARTICLE	IF	CITATIONS
217	Mast cells, basophils, and mastocytosis. , 2013, , 284-297.		3
218	Differential effects of skin nerves on allergic skin inflammation. Allergy: European Journal of Allergy and Clinical Immunology, 2009, 64, 496-497.	5.7	2
219	A Case of Muckle-Wells Syndrome due to novel NLRP3 mutation. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1250-1252.	0.8	2
220	Are we facing a change in the treatment of chronic pruritus?. British Journal of Dermatology, 2019, 181, 877-878.	1.5	2
221	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, diagnostyki i leczenia pokrzywki. Alergologia Polska - Polish Journal of Allergology, 2020, 7, 1-28.	0.0	2
222	A Systematic Review of Aquagenic Urticaria - Subgroups and Treatment Options. Journal of Allergy and Clinical Immunology: in Practice, 2022, , .	3.8	2
223	STAT3 gain-of-function is not responsible for low total IgE levels in patients with autoimmune chronic spontaneous urticaria. Frontiers in Immunology, 0, 13, .	4.8	2
224	Development of a standardized experimental itch model in humans. Journal of the American Academy of Dermatology, 2014, 70, AB42.	1.2	1
225	Nutzen von Mepolizumab bei einer Patientin mit chronischer spontaner Urtikaria. JDDG - Journal of the German Society of Dermatology, 2018, 16, 476-477.	0.8	1
226	Pathomechanismus von AngioÄrdemen. Allergologie, 2013, 36, 85-91.	0.1	1
227	New roles for neurotrophin-3, neurotrophin-4 and brain-derived neurotrophic factor: Involvement in hair growth control. Journal of Dermatological Science, 1998, 16, S9.	1.9	0
228	Modulation of skin mast cell functions in situ by neurotrophin-3. Journal of Dermatological Science, 1998, 16, S165.	1.9	0
229	Viewpoint 1. Experimental Dermatology, 2003, 12, 887-891.	2.9	0
230	Viewpoint 5. Experimental Dermatology, 2006, 15, 924-925.	2.9	0
231	Mast cells, basophils and mastocytosis. , 2008, , 345-360.		0
232	Type 2 Immunity Can Have a Protective Role In Host Defense Against Venoms In Mice. Journal of Allergy and Clinical Immunology, 2014, 133, AB90.	2.9	0
233	IgE Antibodies and FcÎµRI Are Critical For Acquired Resistance Against Honeybee Venom In Mice. Journal of Allergy and Clinical Immunology, 2014, 133, AB225.	2.9	0
234	Wytyczne EAACI/GA2LEN/EDF/WAO dotyczÄ...ce definicji, klasyfikacji, rozpoznawania i leczenia pokrzywki: weryfikacja z 2013 roku z poprawkami. Alergologia Polska - Polish Journal of Allergology, 2015, 2, T1-T23.	0.0	0

#	ARTICLE	IF	CITATIONS
235	Omalizumab normalizes gene expression in lesional skin of patients with chronic spontaneous urticaria: Results from a randomized, double-blind, placebo-controlled study. Journal of the American Academy of Dermatology, 2016, 74, AB64.	1.2	0
236	041 Prevalence, characteristics and burden of pruritus in chronic dermatoses. Journal of Investigative Dermatology, 2017, 137, S199.	0.7	0
237	057 The role of substance P and its receptor NK1R in chronic prurigo: Results from a randomized, controlled trial with topical aprepitant. Journal of Investigative Dermatology, 2017, 137, S202.	0.7	0
238	Omalizumab improves angioedema-related quality of life impairment in chronic spontaneous urticaria patients: Results from the X-ACT study. Journal of the American Academy of Dermatology, 2018, 79, AB209.	1.2	0
239	Ein Fall von Muckle-Wells-Syndrom mit einer neuen NLRP3-Mutation. JDDG - Journal of the German Society of Dermatology, 2018, 16, 1250-1252.	0.8	0
240	Ligelizumab for Chronic Spontaneous Urticaria. New England Journal of Medicine, 2020, 382, 579-580.	27.0	0
241	Inducible Urticarias. , 2021, , 109-132.		0
242	Standard Operating Procedures: A Practical Approach. , 2010, , 141-151.		0
243	Neue Therapeutika beim Hereditären Angioödem – unbeantwortete Fragen beim Hereditären Angioödem. Allergologie, 2013, 36, 120-127.	0.1	0
244	Oral Allergy Syndrome. , 2014, , 37-50.		0
245	Mastzellen und Basophile. , 2016, , 69-75.		0
246	Anpassung der Therapiekonzepte: Chronische spontane Urtikaria – eine Autoimmunkrankheit. , 0, , .		0